← Eichor
Study identifier: NCT00107289 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Condition: Neuroblastoma · Pheochromocytoma  ·  Sponsor: Memorial Sloan Kettering Cancer Center

PhasePhase 2
Planned participants200
Who can joinAll sexes, 1 Year to no upper limit
Healthy volunteersNo

About this study

The purpose of this research study is to find how active and safe 131 I-MIBG is in patients with resistant neuroblastoma, malignant pheochromocytoma and malignant paraganglioma.

This description comes directly from the study's public registry record.

Talk to the study team

Ellen Basu, MD, PhD  ·  212-639-5204

Shakeel Modak, MD  ·  212-639-7623

Always discuss trial participation with your own doctor first.

Locations (1)

Memorial Sloan Kettering Cancer CenterNew York, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT00107289